Thank you for Subscribing to Life Science Review Weekly Brief
With the capacity to sequence more than 20,000 genomes each year, cutting-edge technology offers the most significant levels of precision on a massive scale.
FREMONT, CA: "Illumina has been a pioneer in genomics for more than two decades, and with this new sequencer, we are reinventing the genomics industry once again. Today, we are forging a new path forward to advance more breakthroughs in cancer and genetic disease treatments, precision therapies, and pandemic preparedness. Innovations like NovaSeq X are at the heart of how we will transform patient lives, and this groundbreaking technology will empower researchers, scientists, and clinicians in the fight to diagnose, treat – and eventually cure – disease while making genomics more sustainable and accessible to millions more people around the world." says Francis deSouza, Chief Executive Officer of Illumina
The company's goal is to expand worldwide access to genetic medicine. Their most environmentally friendly high-throughput sequencing reduces packing by 90 percent, plastic waste by 50 percent, and dry ice shipping by 100 percent.
Illumina, one of the global leaders in DNA sequencing and array-based technologies, unveils NovaSeqTM X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the boundaries of what is possible in genomic medicine by enabling faster, more powerful, and more sustainable sequencing.
Using groundbreaking new technology, NovaSeq X Plus can create more than 20,000 whole genomes per year, 2.5 times the throughput of previous sequencers, significantly increasing genomic discoveries and clinical insights to understand the illness and ultimately improve patient lives.
Illumina's revolutionary NovaSeq X Series, a new generation of production-scale sequencers, will push the boundaries of what is achievable in genomic medicine by allowing faster, more powerful, and more sustainable sequencing.